Anti-cancer therapy based on pre-selection of cancers and patients through genomically
characterized and identified molecular biomarkers has seen dramatic improvements in
the treatment for breast cancer, lung cancer, certain leukemias and other malignancies.
For gynecologic cancers, precision medicine through genomic testing has advanced the
identification of high risk individuals as well as the treatment of specific types
of ovarian cancer, i.e. germline BRCA mutated (gBRCAm), but has yet to significantly affect the standard treatment of BRCA wild type (BRCAwt) ovarian cancer, cervical or endometrial cancer. Nonetheless, the genomic characterization
of gynecologic malignancies has provided the foundation for improved understanding
of pathogenesis of gynecologic cancers, treatment advances, and outcome prediction
for women with gynecologic cancers and is certain to have profound impact in the future.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Gynecologic OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Integrated genomic analysis of ovarian cancer.Nature. 2011; 474: 609-615
- Integrated genomic characterization of endometrial carcinoma.Nature. 2013; 497: 67-73
- Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.Cancer. 2013; 119: 3776-3783
- Landscape of genomic alterations in cervical carcinomas.Nature. 2014; 506: 371-375
- Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.JAMA. 2012; 307: 382-390
- PARP inhibitors in ovarian cancer: current status and future promise.Gynecol. Oncol. 2014; 133: 362-369
- Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.J. Clin. Oncol. 2015; 33: 1397-1406
- PARP inhibition in ovarian cancer: state of the science.Gynecol. Oncol. 2015; 136: 8-10
- Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.Clin. Cancer Res. 2014; 20: 764-775
- New perspectives on molecular targeted therapy in ovarian clear cell carcinoma.Br. J. Cancer. 2013; 108: 1553-1559
- Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors.Genome Med. 2015; 7 (in press): 87
- Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.Oncotarget. 2015; 6 (in press)
- Recurrent SMARCA4 mutations in small cell carcinoma of the ovary.Nat. Genet. 2014; 46: 424-426
- Mutation of FOXL2 in granulosa-cell tumors of the ovary.N. Engl. J. Med. 2009; 360: 2719-2729
- Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers.N. Engl. J. Med. 2012; 366: 234-242
- Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva.Gynecol. Oncol. 2012; 127: 141-146
- Whole-genome characterization of chemoresistant ovarian cancer.Nature. 2015; 521: 489-494
- ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.J. Clin. Oncol. 2014; 32 (suppl; abstr TPS5619)
- Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population.J. Clin. Oncol. 2015; 33: 2901-2907
- Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer.J. Natl. Cancer Inst. 2015; 107 (in press)
- Gallagher WM.p53 as a target for the treatment of cancer.Cancer Treat. Rev. 2014; 40: 1153-1160
- Selumetanib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.Lancet Oncol. 2013; 14: 134-140
Article info
Publication history
Published online: December 04, 2015
Accepted:
November 19,
2015
Received:
November 18,
2015
Footnotes
☆Disclosures: Ursula Matulonis: consultant for Astrazeneca, Tesaro, and Genentech/Roche. Joyce Liu: consultant for Astrazeneca and Genentech/Roche and conducted clinical research on trials sponsored by AstraZeneca, Genentech/Roche, Boston Biomedical, Atara Biotherapeutics, and Merrimack Pharmaceuticals. Panagiotis A. Konstantinopoulos: Advisory Board for Vertex Inc.
Identification
Copyright
© 2015 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
